Advisors Management Group’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $446K | Sell |
2,355
-22
| -0.9% | -$4.14K | 0.07% | 115 |
|
|
2026
Q1 | $468K | Buy |
2,377
+29
| +1% | +$5.59K | 0.09% | 112 |
|
|
2025
Q4 | $432K | Hold |
2,348
| – | – | 0.08% | 107 |
|
|
2025
Q3 | $360K | Hold |
2,348
| – | – | 0.06% | 116 |
|
|
2025
Q2 | $328K | Hold |
2,348
| – | – | 0.06% | 119 |
|
|
2025
Q1 | $345K | Hold |
2,348
| – | – | 0.08% | 117 |
|
|
2024
Q4 | $308K | Hold |
2,348
| – | – | 0.07% | 123 |
|
|
2024
Q3 | $366K | Hold |
2,348
| – | – | 0.09% | 116 |
|
|
2024
Q2 | $366K | Hold |
2,348
| – | – | 0.09% | 111 |
|
|
2024
Q1 | $318K | Hold |
2,348
| – | – | 0.08% | 121 |
|
|
2023
Q4 | $316K | Hold |
2,348
| – | – | 0.09% | 116 |
|
|
2023
Q3 | $318K | Sell |
2,348
-39
| -2% | -$5.33K | 0.1% | 111 |
|
|
2023
Q2 | $342K | Sell |
2,387
-70
| -3% | -$10.3K | 0.1% | 105 |
|
|
2023
Q1 | $341K | Sell |
2,457
-130
| -5% | -$17.5K | 0.11% | 102 |
|
|
2022
Q4 | $351K | Hold |
2,587
| – | – | 0.13% | 91 |
|
|
2022
Q3 | $284K | Sell |
2,587
-9
| -0.3% | -$1.14K | 0.11% | 101 |
|
|
2022
Q2 | $343K | Hold |
2,596
| – | – | 0.12% | 98 |
|
|
2022
Q1 | $344K | Hold |
2,596
| – | – | 0.12% | 94 |
|
|
2021
Q4 | $302K | Hold |
2,596
| – | – | 0.09% | 101 |
|
|
2021
Q3 | $312K | Sell |
2,596
-163
| -6% | -$19K | 0.1% | 101 |
|
|
2021
Q2 | $331K | Sell |
2,759
-65
| -2% | -$7.13K | 0.1% | 98 |
|
|
2021
Q1 | $281K | Sell |
2,824
-152
| -5% | -$15.3K | 0.09% | 100 |
|
|
2020
Q4 | $297K | Sell |
2,976
-100
| -3% | -$10.6K | 0.12% | 80 |
|
|
2020
Q3 | $337K | Buy |
3,076
+1
| +0% | +$111 | 0.14% | 75 |
|
|
2020
Q2 | $325K | Buy |
3,075
+69
| +2% | +$7.13K | 0.14% | 71 |
|
|
2020
Q1 | $268K | Sell |
3,006
-9
| -0.3% | -$847 | 0.13% | 77 |
|
|
2019
Q4 | $301K | Hold |
3,015
| – | – | 0.12% | 74 |
|
|
2019
Q3 | $269K | Sell |
3,015
-178
| -6% | -$15.4K | 0.11% | 76 |
|
|
2019
Q2 | $264K | Sell |
3,193
-98
| -3% | -$7.68K | 0.12% | 77 |
|
|
2019
Q1 | $266K | Buy |
3,291
+1
| +0% | +$79 | 0.12% | 76 |
|
|
2018
Q4 | $250K | Sell |
3,290
-326
| -9% | -$25.5K | 0.13% | 71 |
|
|
2018
Q3 | $286K | Buy |
3,616
+1
| +0% | +$76 | 0.13% | 72 |
|
|
2018
Q2 | $254K | Hold |
3,615
| – | – | 0.12% | 70 |
|
|
2018
Q1 | $254K | Sell |
3,615
-125
| -3% | -$8.66K | 0.13% | 71 |
|
|
2017
Q4 | $260K | Hold |
3,740
| – | – | 0.13% | 72 |
|
|
2017
Q3 | $253K | Buy |
3,740
+1
| +0% | +$63 | 0.13% | 69 |
|
|
2017
Q2 | $255K | Sell |
3,739
-29
| -0.8% | -$1.89K | 0.14% | 67 |
|
|
2017
Q1 | $235K | Buy |
+3,768
| New | +$219K | 0.15% | 63 |
|
|
2016
Q1 | – | Sell |
-2,948
| Closed | -$200K | – | 63 |
|
|
2015
Q4 | $200K | Buy |
+2,948
| New | +$193K | 0.16% | 62 |
|
Other funds holding AZN
EP
IA
Advisors Management Group's AZN Position: Q2 2026 in Review
Advisors Management Group reduced its AstraZeneca (AZN) stake by 0.93% in Q2 2026, selling an estimated $4.14K and leaving 2,355 shares worth $446K. The position accounts for 0.07% of the portfolio, ranked #115.
Advisors Management Group first reported a position in AZN in Q4 2015 and has held it in 39 quarters since. The position peaked at $468K in Q1 2026. 1,501 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Advisors Management Group held 2,355 shares of AstraZeneca worth $446K as of Q2 2026.
- Advisors Management Group sold 22 AstraZeneca shares in Q2 2026, an estimated $4.14K.
- AstraZeneca made up 0.07% of Advisors Management Group's portfolio in Q2 2026, its #115 holding.
- Advisors Management Group first reported a position in AstraZeneca in Q4 2015 and has held it in 39 quarters since.
- Advisors Management Group's AstraZeneca position peaked at $468K in Q1 2026.
- 1,501 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Advisors Management Group's 13F filing for Q2 2026, filed 4 Aug 2026.